| abstract |
“FCRN ANTIBODY COMPOSITIONS”. This disclosure relates to compositions that comprise an anti-FcRn antibody, M281. The compositions include the complete, intact antibody and the size variants thereof that do not include two antibody heavy chains and for antibody light chains. Thus, an M281 pharmaceutical composition may include: an antibody comprising a heavy chain comprising the amino acid sequence of SEQ ID NO: 2 and a light chain comprising the amino acid sequence of SEQ ID NO: 1, wherein the composition comprises a major protein component having a molecular weight of 140,000 to 145,000 Da and a secondary protein component of a molecular weight of 118,000 to 120,000 Da. |